Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rivaroxaban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 known ✓ | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.80 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.80 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.80 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.80 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rivaroxaban SCHEMBL77766 | 1.00 | F10 (1.00) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL3914 | 1.00 | F10 (1.00) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL14796329 | 0.99 | F10 (0.98) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL14796410 | 0.95 | F10 (0.90) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL30893049 | 0.94 | F10 (0.90) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL3375861 | 0.93 | F10 (0.86) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL13068882 | 0.92 | F10 (0.85) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL5478295 | 0.92 | F10 (0.85) | F10F2ABCB11ST14CYP1A2 | |
| Rivaroxaban SCHEMBL12396723 | 0.91 | F10 (0.83) | F10F2ABCB11ST14CYP1A2 | |
| SCHEMBL20802158 | 0.91 | F10 (0.83) | F10F2ABCB11ST14CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102762-A1 | TRI-(ADAMANTYL)PHOSPHINES AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2026-04-16 | — | — | US | disclosed |
| US-12539508-B2 | Tri-(adamantyl) phosphines and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2026-02-03 | — | — | US | disclosed |
| EP-4286051-A2 | A METHOD OF CROSS-COUPLING USING A TRANSITION METAL COMPLEX COMPRISING A PAD3 LIGAND | The Trustees of Princeton University (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11794180-B2 | Tri-(adamantyl)phosphines and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-10-24 | — | — | US | disclosed |
| EP-3377221-B1 | A METHOD OF CROSS-COUPLING USING A TRANSITION METAL COMPLEX COMPRISING A PAD3 LIGAND | UNIV PRINCETON (US) | 2023-07-26 | — | — | EP | disclosed |
| US-20230158480-A1 | TRI-(ADAMANTYL)PHOSPHINES AND APPLICATIONS THEREOF | UNIV PRINCETON (US) | 2023-05-25 | — | — | US | disclosed |
| US-11583844-B2 | Tri-(adamantyl)phosphines and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| EP-2705028-B1 | PROCESS FOR THE PREPARATION OF A RIVAROXABAN AND INTERMEDIATES FORMED IN SAID PROCESS | EGYT GYOGYSZERVEGYESZETI GYAR (HU) | 2019-08-21 | — | — | EP | disclosed |
| US-20170267669-A1 | Process for the Preparation of Rivaroxaban | CIPLA LIMITED (IN) | 2017-09-21 | — | — | US | disclosed |
| US-20170267669-A1 | Process for the Preparation of Rivaroxaban | CIPLA LIMITED (IN) | 2017-09-21 | — | — | US | disclosed |
| WO-2014155259-A2 | PROCESS FOR THE PREPARATION OF RIVAROXABAN | GLENMARK PHARMACEUTICALS LIMITED; GLENMARK GENERICS LIMITED (IN) | 2014-10-02 | — | — | WO | disclosed |
| WO-2013120465-A1 | A PROCESS FOR THE PREPARATION OF RIVAROXABAN BASED ON THE USE OF (S)-EPICHLOROHYDRIN | ZENTIVA, K.S. (CZ) | 2013-08-22 | — | — | WO | disclosed |
| US-8101609-B2 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-8101609-B2 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC. (CA) | 2012-01-24 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-7816355-B1 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2010-10-19 | — | — | US | disclosed |
| US-7816355-B1 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2010-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11794180-B2 | Tri-(adamantyl)phosphines and applications thereof | PADI3, ADA, ENTPD3 | F10 4680/4885F2 3889/4885ABCB11 4609/4885 |
| US-11583844-B2 | Tri-(adamantyl)phosphines and applications thereof | PADI3, ADA, ENTPD3 | F10 4680/4885F2 3889/4885ABCB11 4609/4885 |
| US-12539508-B2 | Tri-(adamantyl) phosphines and applications thereof | OTC, AOC3, ICOSLG | F10 3565/4885F2 1116/4885ABCB11 3145/4885 |
| US-20260102762-A1 | TRI-(ADAMANTYL)PHOSPHINES AND APPLICATIONS THEREOF | PTMS, TEC, CD2 | F10 3973/4885F2 1186/4885ABCB11 3513/4885 |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 8/4885F2 2/4885ABCB11 3067/4885 |
| US-20170267669-A1 | Process for the Preparation of Rivaroxaban | F7, F5, F2 | F10 10/4885F2 3/4885ABCB11 2630/4885 |
| US-20230158480-A1 | TRI-(ADAMANTYL)PHOSPHINES AND APPLICATIONS THEREOF | PADI3, ADA, ENTPD3 | F10 4680/4885F2 3889/4885ABCB11 4609/4885 |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 7/4885F2 2/4885ABCB11 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.